Chengdu New Radiomedicine Technology Co., Ltd. (“NRT”), founded in 2016 by veterans in nuclear technology, focuses on the full value chain of medical isotopes production and radiopharmaceutical innovation. The company has multiple branches in China and global presence in the United States and Australia. Our team of 300+ professionals delivers integrated solutions from radiopharmaceutical discovery to global commercialization.

Leveraging rich expertise in nuclear medicine and drug innovation, our cross-disciplinary team of radiochemists, clinical researchers and regulatory experts work together to accelerate radioligand therapy (RLT) advancement. The iCleave™ Technology Platform develops purposely-designed linkers for RLT, optimizing bio-distribution, safety and efficacy. The 68Ga-NRT6020 and 177Lu-NRT6020 Injections for diagnosis and treatment of FAP-positive advanced solid tumors, respectively, have obtained FDA IND clearance and NMPA IND approval, with Phase I patient enrollment in progress. NRT’s proprietary 90Y Carbon Microspheres in late phase clinical development for liver and pancreatic cancers deliver safe and highly effective treatment options to patients using minimally invasive procedures. Additionally, NRT has completed installation of the first 30MeV Cyclone® IKON in Asia and is ready for production of important therapeutic and imaging isotopes. 

NRT is committed to becoming a leading enterprise in the field of innovative radiopharmaceutical development.